• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OrbusNeich launches Combo Plus stent

November 21, 2016 By Sarah Faulkner

OrbusNeich launches Combo stentOrbusNeich said today that it launched the latest version of its dual-therapy stent, the Combo Plus, featuring an antibody biological coating designed to promote vessel healing in patients with complex coronary artery disease.

After the stent is implanted, the biological coating captures endothelial progenitor cells and kicks off formation of an endothelial layer. A coating of bioabsorbable polymer elutes sirolimus to inhibit neointimal hyperplasia, or the growth and movement of vascular smooth muscle cells in the innermost layer of the artery. The accelerated healing process may reduce adverse events and lead to a quicker return of functionality in patients with coronary stenosis, according to the Hong Kong-based company.

The dual therapy stent uses an enhanced balloon catheter, featuring a lower profile design, lubricious coating and reduced shaft diameters.

“Our design improvements provide superior deliverability and powerful performance for complex daily practice,” chairman David Chien said in prepared remarks. “Combo Plus offers physicians a compelling new treatment option for patients with coronary artery disease.”

OrbusNeich 1st launched the Combo dual therapy stent in 2013, touting it as the world’s 1st dual-therapy stent designed to accelerate endothelial coverage while controlling neointimal profileration. The device is supported by a family of clinical studies, totaling more than 6,000 patients across more than 26 countries.

Earlier this year, the company expanded its portfolio to include its Jade and Scoreflex percutaneous transluminal angioplastyballoon devices designed to treat peripheral artery disease. The balloon devices are OrbusNeich’s 1st foray into lower limb and arteriovenous fistula intervention.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Vascular Tagged With: OrbusNeich

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS